Prevention Of Novel Coronavirus Pneumonia Research Articles

Annual review of venous thromboembolism in 2021

In the past year, significant progress has been made in the field of venous thromboembolism (VTE) including risk assessment and anticoagulation prevention, diagnostic strategies and model exploration, new drug development and disease management. Particularly, major breakthroughs have been made in the prevention of VTE with FXI inhibitors and the prevention of novel coronavirus pneumonia with coagulation alterations and anticoagulation interventions. Here, we reviewed the progress and achievements in the field of VTE in the past year, aiming to provide evidence and ideas for the diagnosis, treatment and future studies of VTE.

Protease Inhibitor Use in COVID-19.

The outbreak of a large plaque, novel coronavirus pneumonia (NCP), which also named Coronavirus Disease 2019 (COVID-19) by the WHO, has detrimentally affected the livelihood and health of people in China. During the spread of COVID-19, colleagues who have been working at the frontline have had to face many new challenges in the treatment and prevention of NCP. Therefore, we have provided suggestions for the diagnosis, treatment, and prevention of the novel coronavirus pneumonia in the current epidemic situation based on the latest reports and the experience of doctors treating COVID-19 in our hospital. We recommend lopinavir/ritonavir as the effective drugs for antiviral treatment according to our experience in administering lopinavir/ritonavir to COVID-19 patients and the successful cases of these drugs in treating MERS and SARS, but need more clinical data to prove their efficacy in treating COVID-19.

Emergency management and protection measures during epidemics of Novel coronavirus pneumonia

In order to enhance the abilities of preventing and controlling Novel coronavirus pneumonia in staffs in nursing home and ensure the orderly and efficient performance of prevention and control work for Novel coronavirus pneumonia, this research is aimed to provide references for prevention of Novel coronavirus pneumonia and safe care for elderly people during outbreak from aspects of establishing an overall and coordinated management mechanism, improving the emergency response to epidemic prevention and control, strictly managing the entrance and exit of nursing home, doing a good job in isolation of the elderly people who just need to move in, and developing personalized psychological consolation.

Countermeasures for Hemodialysis Patients with Fever in Non-Designated Hospitals during the Epidemic Period of Novel Coronavirus Pneumonia (COVID-19)

Objective: To explore the effect of countermeasures for hemodialysis patients with fever during the incubation period of novel coronavirus pneumonia (NCP) in a non-designated hospital. Methods: For 22 hemodialysis patients with fever in our hospital, we developed a specialist program based on the latest NCP treatment guidelines for nephrology and hemodialysis. We trained medical staff accurately and rapidly online. According to the specialist program, we implemented meticulous treatment for patients including dialysis, psychological and environmental care. We provided protection of medical staff in wards and dialysis rooms. Medical waste was deposited properly. Moreover, we implemented quality improvement in a timely manner according to the situation. Results: The 22 hemodialysis patients with fever in our hospital were not infected with novel coronavirus 2019. The epidemiological screening rate was 100%, and the percentage of family care giving was reduced by 29.8%. All medical stuff were uninfected. The patient’s satisfaction rate in the observation group is higher than that in the control group (96% vs. 74%, p = 0.048). Conclusion: The countermeasures for hemodialysis patients with fever developed by our specialty were effective. We can satisfy requirements for the NCP prevention for hemodialysis patients with fever in non-designated hospitals through implementing these countermeasures.